Clinical Trial

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The study will evaluate the safety, tolerability, and immunogenicity of a single injection of up to 4 dose levels of IN006 in younger adults and 3 dose levels of IN006 in older adults; of a revaccination of IN006 given approximately 12 months after the initial vaccination in older adults.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-28; most recent amendment 2026-04-10.
Trial Details
NCT Number NCT06287450
Lead Sponsor Shenzhen Shenxin Biotechnology Co., Ltd
Conditions Respiratory Syncytial Virus Infections
Enrollment 200 participants
Start Date 2026-12
Primary Completion 2028-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-13